Purpose: Peritoneal carcinomatosis in gastric cancer (GC) patients results in extremely poor prognosis. Malignant ascites samples are the most appropriate biological material to use to evaluate biomarkers for peritoneal carcinomatosis. This study identified exosomal microRNAs (miRNAs) differently expressed between benign liver cirrhosis-associated ascites (LC-ascites) and malignant gastric cancer-associated ascites (GC-ascites), and validated their role as diagnostic biomarkers for GC-ascites.

Materials and Methods: Total RNA was extracted from exosomes isolated from 165 ascites samples (73 LC-ascites and 92 GC-ascites). Initially, microarrays were used to screen the expression levels of 2,006 miRNAs in the discovery cohort (n=22). Subsequently, quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analyses were performed to validate the expression levels of selected exosomal miRNAs in the training (n=70) and validation (n=73) cohorts. Furthermore, carcinoembryonic antigen (CEA) levels were determined in ascites samples.

Results: The miR-574-3p, miR-181b-5p, miR-4481, and miR-181d were significantly downregulated in the GC-ascites samples compared to the LC-ascites samples, and miR-181b-5p showed the best diagnostic performance for GC-ascites (area under the curve [AUC]=0.798 and 0.846 for the training and validation cohorts, respectively). The diagnostic performance of CEA for GC-ascites was improved by the combined analysis of miR-181b-5p and CEA (AUC=0.981 and 0.946 for the training and validation cohorts, respectively).

Conclusions: We identified exosomal miRNAs capable of distinguishing between non-
malignant and GC-ascites, showing that the combined use of miR-181b-5p and CEA could improve diagnosis.

**Keywords:** Ascites; Biomarkers; Exosomes; Gastric cancer; MicroRNA

**INTRODUCTION**

Peritoneal carcinomatosis is the most common metastatic pattern in patients with advanced gastric cancer (GC). Surgical resection is usually not indicated and the response to conventional systemic therapy is poor [1]. Furthermore, peritoneal carcinomatosis with malignant ascites is associated with poor prognosis and is a major cause of death in patients with advanced GC [1,2]. Therefore, the accurate diagnosis of peritoneal carcinomatosis is essential for treatment selection and prognosis in patients with GC. Currently, cytological analysis of accumulated peritoneal fluid or ascites is performed to confirm peritoneal carcinomatosis because of its high specificity. However, its sensitivity is low [3], and patients with GC are sometimes required to undergo invasive examinations, such as laparoscopy or laparotomy, for the acquisition of peritoneal tissues. Therefore, a more sensitive and non-invasive method is necessary to detect peritoneal carcinomatosis or malignant ascites.

MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs that repress protein translation by binding to target mRNAs [4]. Numerous miRNAs are aberrantly expressed in virtually all types of human cancers, including GC, and act as either oncogenes or tumor suppressors [5]. One of the remarkable aspects of miRNAs is their high degree of stability in the extracellular environment. MiRNAs can be enclosed in small vesicles, such as exosomes, apoptotic bodies, or microvesicles, which shield them from degradative enzymes [6]. Previous studies have mostly examined circulating extracellular miRNAs in serum or plasma. However, they can also be reproducibly retrieved from non-blood body fluids, including tears, saliva, breast milk, cerebrospinal fluid, urine, feces, pleural fluid, and ascites [6].

A specific peritoneal metastatic tumor-derived miRNA profile is more likely to be detected in malignant ascites than in primary tumor tissue or blood. In the current study, we searched for exosomal miRNAs that were differently expressed between benign liver cirrhosis-associated ascites (LC-ascites) and malignant gastric cancer-associated ascites (GC-ascites). Furthermore, we compared the discriminating abilities of these exosomal miRNA biomarkers with those of carcinoembryonic antigen (CEA), the most commonly used tumor marker, especially used for gastrointestinal cancers [7,8].

**MATERIALS AND METHODS**

**Study design and ascites samples**

The overall study design and workflow are shown in Fig. 1. The 165 ascites samples (73 LC-ascites, and 92 GC-ascites), originating from 4 different centers, were obtained from the National Biobank of Korea between January 2012 and August 2017. The ascites samples were allocated to 3 cohorts in chronological order: 22 samples in the discovery cohort (10 LC-ascites and 12 GC-ascites), 70 in the training cohort (30 LC-ascites and 40 GC-ascites), and 73 in the validation cohort (33 LC-ascites and 40 GC-ascites).
The LC-ascites samples were obtained from patients with LC and no clinical or radiological evidence of malignancy. These patients were diagnosed on the basis of clinical features and the lack of evidence of malignant cells in the ascites samples. The GC-ascites samples were obtained from patients with a histological diagnosis of primary gastric adenocarcinoma, showing no evidence of other malignant tumors. Ascites samples were collected at the time of diagnostic or therapeutic paracentesis in GC patients with ascites. All GC-ascites samples were analyzed via cytological analysis and were pathologically confirmed as positive for adenocarcinoma. All ascites samples were centrifuged at 3,200×g for 10 minutes to eliminate large cell particles and cell debris. The supernatant from each sample was aliquoted into microcentrifuge tubes and stored at −80°C until further analysis.

Fig. 1. Overview of the study design.
LC = liver cirrhosis; GC = gastric cancer; qRT-PCR = quantitative reverse transcription-polymerase chain reaction; miRNA = microRNA.
The study protocol was reviewed and approved by the Institutional Review Board of the Chungbuk National University Hospital, South Korea (IRB approval number: CBNUH 2017-05-014), and written informed consent was obtained from all study participants.

**Exosome isolation**

The exosomes from each ascites sample (500 μL of supernatant) were precipitated using the miRCURY Exosome Isolation Kit (Exiqon, Woburn, MA, USA), in accordance with the manufacturer’s instructions. This kit is a valuable alternative to ultracentrifugation and has been used as a commercial exosome isolation kit with reliable quality [9,10]. In brief, 10-mL samples were initially centrifuged at 3,200×g for 5 minutes to eliminate cell debris, and 4 mL precipitation buffer was added. Mixtures were vortexed and incubated at 4°C for 60 minutes and centrifuged at 3,200×g for 30 minutes at 20°C to precipitate exosome pellets. The supernatant was discarded completely and the pellet was re-centrifuged for 5 seconds and the residual supernatant was discarded. All exosomes were stored at −80°C immediately after isolation and prior to miRNA quantification.

**Total RNA extraction and analysis**

Total RNA was extracted from exosomes using the Trizol LS Reagent (Molecular Research Center, Cincinnati, OH, USA) in accordance with the manufacturer’s instructions. Total exosomal RNA was quantified by measuring the absorbance at 260 nm and RNA integrity was confirmed using a Bioanalyzer 2100 (Agilent Technologies, San Carlos, CA, USA).

**miRNA microarray**

miRNA profiling was performed using the Agilent Human miRNA Microarray Release 19.0 platform instrument (Agilent Technologies) comprising 2,006 human miRNAs. In brief, cyanine 3-labeled complementary RNA (cRNA) was generated using Agilent’s Low RNA Input Linear Amplification kit with 500 ng total RNA. Labeled cRNA was then quantified using Nanodrop spectrophotometer. Labeled cRNA was applied on the microarray (8×60K; Agilent technologies) using Agilent Gene Expression Hybridization Kit. The hybridized microarray was washed using Agilent Gene Expression Wash Buffer Kit. The microarray chip was scanned using Agilent’s DNA microarray scanner and the raw signal density was acquired from the feature Extraction software. Data analysis was performed using GeneSpring GX software v.12 (Agilent Technologies) and the DAVID Bioinformatics tool (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA).

**Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)**

Reverse transcription of 100 ng of isolated exosomal miRNA was carried out using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), in accordance with the manufacturer’s protocol, and specific miRNA primers provided with the TaqMan MicroRNA Assay (Applied Biosystems). Candidate miRNAs were quantified using qRT-PCR and the Applied Biosystems 7500 Fast Real-Time PCR System along with TaqMan Universal PCR Master Mix (Applied Biosystems). All reactions were carried out in triplicate, and relative miRNA expression levels were calculated using the 2−ΔΔCt method.

The following criteria were applied to identify reference miRNAs for qRT-PCR analyses: the miRNA was detected in all ascites samples, the mean fold-change in the expression levels between the LC-ascites and GC-ascites samples was <1.3, and the expression level did not differ significantly (P>0.05) between the 2 sample sets. Based on these criteria, 3 miRNAs (miR-4270, miR-197-5p, and miR-642a-3p) were identified as reference miRNAs in
the discovery cohort (Supplementary Table 1). Of these, miR-642a-3p was the most stably expressed in the LC-ascites and GC-ascites samples in the training and validation sets (Supplementary Fig. 1), and was used as an endogenous control for data normalization.

**Immunooassay for CEA in ascites samples**

CEA expression levels in ascites samples were quantified using an Architect i4000SR chemiluminescent enzyme immunooassay (Abbott Laboratories, Abbott Park, IL, USA) in accordance with the manufacturer’s instructions.

**Statistical analysis**

Mann-Whitney unpaired tests were performed to assess differences in the expression levels of miRNAs and CEA between LC-ascites and GC-ascites samples. We plotted receiver operating characteristic (ROC) curves and calculated the area under the curve (AUC) of significantly differentially expressed miRNAs and CEA to predict the diagnostic performance. The optimal cut-off points for candidate markers were determined based on the highest combined sensitivity and specificity for detection in the ROC curve analysis (with a specificity of least 0.6). Risk scores were assigned to all patients in accordance with a linear combination between the expression levels of the selected miRNAs and CEA, weighted in accordance with the regression coefficient. Furthermore, we conducted Stepwise Cox regression and stratification analyses. All statistical analyses were performed using the IBM SPSS Statistics software version 21.0 (IBM Corp., Armonk, NY, USA) and MedCalc software version 18.9.1 (MedCalc, Mariakerke, Belgium). All P-values were 2-sided and P-values below 0.05 were considered statistically significant.

**RESULTS**

**Patient characteristics**

Table 1 shows the baseline characteristics of the study participants. The median follow-up period was 50.1 months (range: 17.1–76.2 months) in the LC-ascites group, and no

| Characteristic | Discovery cohort (n=22) | Training cohort (n=70) | Validation cohort (n=73) |
|---------------|------------------------|------------------------|--------------------------|
|               | LC (n=10) | GC (n=12) | LC (n=30) | GC (n=40) | LC (n=33) | GC (n=40) |
| No. of patients | 10 | 12 | 30 | 40 | 33 | 40 |
| Age (yr)       | 61.1±10.2 | 55.8±17.7 | 58.5±13.2 | 54.5±14.9 | 58.1±12.9 | 63.0±13.9 |
| Sex            |           |           |           |           |           |           |
| Male           | 8 (80.0) | 17 (56.7) | 24 (72.7) | 28 (70.0) |
| Female         | 2 (20.0) | 4 (33.3) | 3 (9.1)   | 2 (1.0)   |
| Etiology of LC |           |           |           |           |           |           |
| Hepatitis B    | 5 (50.0) | 16 (53.3) | 18 (54.5) |
| Hepatitis C    | 1 (10.0) | 2 (6.7)   | 3 (9.1)   |
| Alcoholic      | 4 (40.0) | 9 (30.0)  | 10 (30.3) |
| Unknown        | 0 | 3 (10.0) | 2 (6.1)   |
| Histological classification of primary tumor | | | | |
| Tubular adenocarcinoma | | | | |
| Well differentiated | 2 (16.7) | 1 (2.5) | 2 (5.0) |
| Moderately differentiated | 2 (16.7) | 11 (27.5) | 14 (35.0) |
| Poorly differentiated | 4 (33.3) | 13 (32.5) | 11 (27.5) |
| Mucinous carcinoma | 1 (8.3) | 3 (7.5) | 1 (2.5) |
| Poorly cohesive carcinoma | 3 (25.0) | 11 (27.5) | 10 (25.0) |
| Mixed adenocarcinoma | 0 | 1 (2.5) | 2 (5.0) |

Values are presented as mean±standard deviation or number of patients (%)

LC = liver cirrhosis; GC = gastric cancer.
malignancies, including GC, were identified during this period. The most common cause of LC in the LC-ascites group was hepatitis B (50.0%–54.5%), followed by alcoholism (30.0%–40.0%). More than half of the patients in the GC-ascites group (52.5%–60.0%) were pathologically diagnosed with poorly differentiated tubular adenocarcinoma or poorly cohesive carcinoma of the stomach.

**Microarray analysis in the discovery cohort and selection of candidate exosomal miRNAs**

Microarray analysis revealed 36 miRNA variations with a fold-change ≥2.0 and a P<0.05 that could distinguish between LC and GC-ascites (Table 2). These exosomal miRNAs were significantly less expressed in the GC-ascites group than in the LC-ascites group (Fig. 2). Their relative expression levels were then measured via qRT-PCR analysis; 7 miRNAs (miR-574-3p, miR-197-3p, miR-181b-5p, miR-4481, miR-4701-3p, miR-623, and miR-181d) were considered candidate biomarkers and analyzed further (Table 2 and Supplementary Fig. 2).

| miRNA      | Fold change (LC/GC) | P-value |
|------------|---------------------|---------|
| miR-574-3p*| −7.74               | 0.011   |
| miR-197-3p*| −5.63               | 0.011   |
| miR-181b-5p*| −12.49             | 0.018   |
| miR-100-5p  | −3.80               | 0.019   |
| miR-636     | −4.36               | 0.019   |
| miR-4481    | −7.64               | 0.026   |
| miR-4701-3p*| −5.32              | 0.026   |
| let-7e-5p   | −4.22               | 0.031   |
| miR-103a-3p | −5.34               | 0.031   |
| miR-10a-5p  | −3.55               | 0.031   |
| miR-125a-5p | −3.46               | 0.031   |
| miR-125b-5p | −2.76               | 0.031   |
| miR-127-3p  | −3.80               | 0.031   |
| miR-142-3p  | −4.08               | 0.031   |
| miR-146b-5p | −3.96               | 0.031   |
| miR-204-5p  | −3.95               | 0.031   |
| miR-221-3p  | −3.40               | 0.031   |
| miR-254-5p  | −2.72               | 0.031   |
| miR-265-5p  | −3.71               | 0.031   |
| miR-27b-5p  | −3.61               | 0.031   |
| miR-29b-3p  | −3.33               | 0.031   |
| miR-30b-5p  | −2.49               | 0.031   |
| miR-342-3p  | −2.79               | 0.031   |
| miR-34a-5p  | −2.52               | 0.031   |
| miR-385a-3p | −3.83               | 0.031   |
| miR-378a-3p | −3.59               | 0.031   |
| miR-3907    | −2.54               | 0.031   |
| miR-4462    | −2.58               | 0.031   |
| miR-4711-3p | −3.80               | 0.031   |
| miR-6703    | −3.33               | 0.031   |
| miR-99a-5p  | −3.95               | 0.031   |
| miR-99b-5p  | −4.06               | 0.031   |
| miR-623*    | −6.43               | 0.032   |
| miR-181d*   | −10.36              | 0.034   |
| miR-595     | −2.21               | 0.046   |
| miR-1587    | −5.43               | 0.048   |

LC = liver cirrhosis; GC = gastric cancer; miRNA = microRNA; qRT-PCR = quantitative reverse transcriptase-polymerase chain reaction; LC-ascites = liver cirrhosis-associated ascites; GC-ascites = gastric cancer-associated ascites.

*The miRNAs with significant differential expression between the LC-ascites and GC-ascites samples in qRT-PCR analysis.
Validation of differentially expressed exosomal miRNAs in the training and validation cohorts

The expression levels of the 7 candidate miRNAs identified in the discovery cohort were examined in the training cohort of 70 ascites samples via qRT-PCR analysis. In the training cohort, 5 of these miRNAs (miR-574-3p, miR-197-3p, miR-181b-5p, miR-4481, and miR-181d) were significantly downregulated in the GC-ascites samples than in the LC-ascites samples (Fig. 3A). The expression levels of these miRNAs were then further examined in the validation cohort of 73 ascites samples. In the validation cohort, 4 of the 5 miRNAs (miR-574-3p, miR-181b-5p, miR-4481, and miR-181d) were significantly downregulated in the GC-ascites than in the LC-ascites samples (Fig. 3B).

Diagnostic performance of exosomal miRNAs and CEA in the training and validation cohorts

The performances of differentially expressed exosomal miRNAs and CEA as individual diagnostic biomarkers of GC-ascites were evaluated via ROC curve analysis in the training and validation cohorts (Table 3).
The 5 differentially expressed miRNAs in the training cohort exhibited AUC values ranging from 0.688 to 0.798. MiR-181b-5p displayed the highest value (0.798), with a sensitivity of 87.5% and a specificity of 73.3% (Fig. 4A). The AUC for CEA was 0.956, with a sensitivity of 92.5% and a specificity of 100% with a cut-off value of 2.2 ng/mL (Fig. 4B). When the cut-off

Fig. 3. The qRT-PCR analysis of exosomal miRNA expression in the training (A) and validation (B) cohorts. Statistically significant differences were determined using Mann-Whitney tests, and)
SD = standard deviation; LC-ascites = liver cirrhosis-associated ascites; GC-ascites = gastric cancer-associated ascites; ns = not significant; qRT-PCR = quantitative reverse transcriptase-polymerase chain reaction.
*P<0.05; †P<0.001.

The 5 differentially expressed miRNAs in the training cohort exhibited AUC values ranging from 0.688 to 0.798. MiR-181b-5p displayed the highest value (0.798), with a sensitivity of 87.5% and a specificity of 73.3% (Fig. 4A). The AUC for CEA was 0.956, with a sensitivity of 92.5% and a specificity of 100% with a cut-off value of 2.2 ng/mL (Fig. 4B). When the cut-off

Fig. 4. ROC curve analysis for the diagnosis of GC-ascites in the training (A-D) and validation (E-H) cohorts. Each panel shows the AUC, sensitivity, and specificity values for miR-181b-5p (A, E), CEA (B, F), CEA+miRNA panel (C, G), and CEA+miR-181b-5p (D, H).
ROC = receiver operating characteristic; AUC = area under the curve; GC-ascites = gastric cancer-associated ascites; CEA = carcinoembryonic antigen; miRNA = microRNA.
The value of CEA was analyzed at 5.0 ng/mL, which is currently considered the cut-off value for malignancy in clinical practice, the sensitivity and specificity of CEA were 82.5% and 100%, respectively. The AUC values resulting from the combinations of CEA with the 5-miRNA panel and with the sole miR-181b-5p were 0.980 and 0.981, respectively (Fig. 4C and D), and both combinations displayed a sensitivity of 92.5% and a specificity of 100%.

The AUC values for the 4 differentially expressed miRNAs identified in the validation cohort ranged from 0.777 to 0.846, and the AUC of miR-181b-5p was the highest at 0.846, with a sensitivity of 87.5% and a specificity of 78.8% (Fig. 4E). The AUC for CEA was 0.885, with a sensitivity of 87.5% and a specificity of 81.8% with a cut-off value of 1.0 ng/mL (Fig. 4F).

The AUC value of CEA was analyzed at 5.0 ng/mL, which is currently considered the cut-off value for malignancy in clinical practice, the sensitivity and specificity of CEA were 82.5% and 100%, respectively. The AUC values resulting from the combinations of CEA with the 5-miRNA panel and with the sole miR-181b-5p were 0.980 and 0.981, respectively (Fig. 4C and D), and both combinations displayed a sensitivity of 92.5% and a specificity of 100%.

The AUC values for the 4 differentially expressed miRNAs identified in the validation cohort ranged from 0.777 to 0.846, and the AUC of miR-181b-5p was the highest at 0.846, with a sensitivity of 87.5% and a specificity of 78.8% (Fig. 4E). The AUC for CEA was 0.885, with a sensitivity of 87.5% and a specificity of 81.8% with a cut-off value of 1.0 ng/mL (Fig. 4F).

When the cut-off value of CEA was analyzed at 5.0 ng/mL, the sensitivity and specificity of CEA were 60% and 100%, respectively. The AUC value for the combination of the 4-miRNA panel and CEA was 0.901, with a sensitivity of 85.0% and a specificity of 90.9% (Fig. 4G); the performance was improved (AUC=0.946) when miR-181b-5p was combined with CEA, with a sensitivity of 82.5% and a specificity of 96.7% (Fig. 4H).

**DISCUSSION**

To our knowledge, this study is the first comprehensive and large-scale evaluation of exosomal miRNAs isolated from malignant ascites in GC. Our results showed that specific exosomal miRNAs in ascites potentially distinguished benign ascites from malignant GC-ascites. The expression levels of miR-574-3p, miR-181b-5p, miR-4481, and miR-181d were significantly lower in GC-ascites than in LC-ascites. Among these miRNAs, miR-181b-5p displayed the best diagnostic performance. Compared with that of the most commonly used miRNAs.
tumor marker in the ascites samples, CEA, the diagnostic performance of miR-181b-5p was lower in the training cohort but comparable in the validation set. However, the sensitivity of miR-181b-5p was superior to that of CEA, using the CEA cut-off value of 5.0 ng/mL, which is the general clinical cut-off value for malignancy. Finally, the diagnostic performance of CEA for GC-ascites was improved when this marker was analyzed with miR-181b-5p.

Peritoneal carcinomatosis is associated with poor prognosis in almost all cancers. Hence, accurate diagnosis of this condition is crucial. Furthermore, when cancer patients develop ascites, several comorbid diseases other than malignant ascites, including benign liver disease, heart failure, renal disease, or infections should be considered, although the incidences of these conditions are very low. It is also important to accurately diagnose microscopic peritoneal metastasis. Cytological examination of intraoperatively collected peritoneal lavage fluid is performed to diagnose microscopic peritoneal metastasis [11,12]. Ascites or peritoneal lavage fluid samples are more suitable for evaluation of peritoneal carcinomatosis than primary tumor tissues or blood samples because of their closer proximity and direct contact with tumors within the peritoneum and omentum. Several recent studies have described miRNAs in ascites or peritoneal lavage fluid as putative diagnostic biomarkers of malignant ascites in ovarian cancer or GC [13-18] (Supplementary Table 2). Recently, Tokuhisa et al. [15] examined exosomal miRNA expression in peritoneal lavage fluid and ascites from GC patients with peritoneal metastasis and reported significant upregulation of miR-21 and miR-1225-5p in the peritoneal lavage fluid of patients with serosa-invasive GC (T4) than in those of patients with non-serosa-invasive disease (T1-3). Furthermore, Schindler et al. [18] reported that not only patients with GC but also, in general, patients with peritoneal carcinomatosis displayed significantly higher levels of miR-21 and miR-186 in ascites samples in comparison with patients with portal hypertension. However, most studies examining peritoneal lavage fluid or ascites analyzed relatively small numbers of miRNAs and few ascites samples for a comprehensive and systematic validation of diagnostic biomarkers of peritoneal carcinomatosis with malignant ascites. In the current study, we used microarrays to screen a large number of miRNAs in ascites samples and validated differentially expressed exosomal miRNAs, using relatively large, independent cohorts obtained from 4 different medical centers. Furthermore, we compared the exosomal miRNA profiles of GC-ascites samples containing adenocarcinoma cells with those of tumor-free benign LC-ascites to evaluate potential diagnostic biomarkers for GC-ascites.

Furthermore, we compared the distinguishing potential of exosomal miRNA biomarkers with that of CEA, the most commonly used tumor marker. The AUC value of CEA of the GC-ascites was 0.956 in the training cohort and 0.885 in the validation cohort, indicating a relatively high diagnostic value for diagnosing GC-ascites. In particular, the sensitivity of CEA in the ascites was 92.5% in the training cohort and 87.5% in the validation cohort, greater than 30%–70% of previously reported values [7,19-21]; thus, the sensitivity of CEA for malignant ascites may have been overestimated. This facilitated the analysis of only GC-ascites samples, confirmed with adenocarcinoma, to clarify the diagnostic value of exosomal miRNA for GC-ascites. Malignant ascites display a positive result on cytological analysis only 40%–60% of the time [3]; CEA levels in malignant ascites with negative results on cytological analysis were lower than those with positive results on cytological analysis [22]. In addition, the optimal diagnostic cut-off value of CEA for GC-ascites was determined using ROC curve analysis with the highest sensitivity and specificity to diagnose GC-ascites; consequently, the cut-off value of CEA was 2.2 ng/mL in the training cohort and 1.0 ng/mL in the validation cohort. These cut-off values were lower than 5.0 ng/mL, which is currently considered a clinical cut-off value for malignancy. When the cut-off value of CEA was analyzed at 5.0 ng/mL in our cohort, the sensitivity of CEA for GC-ascites
was decreased. Thus, the cut-off value of CEA contributed to the high sensitivity of CEA in the present ascites samples. The cut-off value of CEA of the ascites is reportedly less than 5.0 ng/mL in diagnosing malignant ascites [19,22,23]; therefore, a lower cut-off than 5.0 ng/mL (for serum CEA) should be considered in ascites samples, and further studies on appropriate diagnostic cut-offs for malignant ascites in ascites samples are warranted.

The levels of miR-574-3p, miR-181b-5p, miR-4481, and miR-181d were significantly lower in the GC-ascites samples than in LC-ascites samples. Among these miRNAs, miR-181b-5p displayed the best diagnostic performance for GC-ascites. MiR-181b expression has been analyzed in many types of human cancer, and contrasting effects were apparently observed in different cancer types. For example, miR-181b is upregulated in lung, colon, and breast tumors but downregulated in gliomas [24-27]. Regarding GC, some studies have reported oncogenic properties for miR-181b, whereas others report its role as a tumor suppressor. Several studies have reported that miR-181b is significantly overexpressed in GCs compared to normal gastric tissue [28,29]. In addition, in vitro studies revealed that miR-181b can inhibit tumor suppressing genes such as caudal-type homeobox 2 (CDX2) or tissue inhibitor of metalloproteinase 3 (TIMP3) [30,31]. However, other studies have reported that miR-181b is downregulated in the serum of patients with GC compared to normal gastric tissue and control serum, respectively [32,33]. Furthermore, in vitro studies have reported that miR-181b overexpression suppresses proliferation and induces apoptosis in GC cells through negative regulation of the oncogene cAMP responsive element binding protein 1 (CREB1) [34]. In addition, miR-181b can inhibit aerobic glycolysis of tumor cells, termed the “Warburg effect,” suggesting that it may play a novel role in metabolic reprogramming in GC cells [35]. Previous functional studies in gliomas reported that miR-181b suppresses tumor growth by targeting the insulin-like growth factor 1 receptor (IGF-1R) oncogene [27]. These apparently discordant findings potentially reflect the differences in miR-181b target genes in various cancers or even in different microenvironments associated with the same cancer type.

In the current study, we could not compare miRNA expression profiles of GC-ascites samples with those of normal peritoneal fluids because paracentesis is an invasive method that cannot be performed for healthy volunteers. Therefore, we harvested LC-ascites samples as a control because LC is the most common cause of benign ascites. Several recent studies have reported that miR-181b, miR-574-3p, and miR-181d were upregulated in patients with LC compared to healthy controls [36-38]. Therefore, it is unclear whether downregulation of these identified exosomal miRNAs in GC-ascites, compared to the LC-ascites, reflects their role as tumor suppressors or, on the contrary, is a consequence of abnormal regulation of these miRNAs in LC-ascites. It would be ideal to compare benign and malignant ascites samples in the same peritoneal cavity within the peritoneum, which comprises serous membranes and a network of mesothelial cells and collagen.

In conclusion, we identified several exosomal miRNAs in ascites with clinical significance in diagnosing GC-ascites and our results show that the combination of miR-181b-5p and CEA profiling displayed an optimal diagnostic performance. However, false-positive findings are a serious concern with respect to the type of diagnostic biomarkers, especially malignancy. Therefore, miR-181b-5p expression in ascites should not be considered an alternative to cytological analysis (the latter being a reliable confirmative diagnostic method with high specificity for malignant ascites). As a single biomarker, its diagnostic value is not as adequate owing to its lower specificity than CEA, a commonly used biomarker. However, the combination of CEA and miR-181b-5p may serve as a potential diagnostic biomarker to
Exosomal miRNAs from Malignant Ascites

distinguish between non-malignant and GC-ascites, especially when diagnosing ascites with negative or inconclusive cytological findings. Further functional analyses are required to determine the relevant functional targets of the identified candidate miRNA biomarkers and the biological significance of their differential expression in GC-ascites.

ACKNOWLEDGMENTS

All ascites samples and data in this study were provided by the Biobank of Chungbuk National University Hospital, Gyeongsang National University Hospital, Chonnam National University Hwasun Hospital, and Chonbuk National University Hospital, members of the Korea Biobank Network, which are supported by the Ministry of Health, Welfare and Family Affairs.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Microarray expression profile of candidate reference miRNAs in the discovery cohort

Click here to view

Supplementary Table 2
Summary of published studies examining miRNAs in malignant ascites samples

Click here to view

Supplementary Fig. 1
The qRT-PCR analysis of the expression levels of candidate reference miRNAs in the training and validation cohorts. Statistically significant differences were determined using the Mann-Whitney test.

Click here to view

Supplementary Fig. 2
The qRT-PCR analysis showing differential expression of 7 miRNAs between LC-ascites and GC-ascites samples in the discovery cohort. Statistically significant differences were determined using Mann-Whitney tests.

Click here to view

REFERENCES

1. Leiting JL, Grotz TE. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018;10:282-289.
2. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 2014;134:622-628.

https://jgc-online.org  https://doi.org/10.5230/jgc.2019.19.e27
3. Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol 2015;21:10936-10947.
PUBMED | CROSSREF

4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233.
PUBMED | CROSSREF

5. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 2015;15:321-333.
PUBMED | CROSSREF

6. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-477.
PUBMED | CROSSREF

7. Ahadi M, Tehranian S, Memar B, Vossoughinia H, Salari M, Eskandari E, et al. Diagnostic value of carcinoembryonic antigen in malignancy-related ascites: systematic review and meta-analysis. Acta Gastroenterol Belg 2014;77:418-424.
PUBMED

8. Han ES, Lee HH, Lee JS, Song KY, Park CH, Jeon HM. At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment. J Gastric Cancer 2014;14:123-128.
PUBMED | CROSSREF

9. Helwa I, Cai I, Drewry MD, Zimmerman A, Dinkins MB, Khaled ML, et al. A comparative study of serum exosome isolation using differential ultracentrifugation and three commercial reagents. PLoS One 2017;12:e0170628.
PUBMED | CROSSREF

10. Markowska A, Pendergrast RS, Pendergrast JS, Pendergrast PS. A novel method for the isolation of extracellular vesicles and RNA from urine. J Circ Biomark 2017;6:1849454417712666.
PUBMED | CROSSREF

11. Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer 2018;21:10-18.
PUBMED | CROSSREF

12. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48.
PUBMED | CROSSREF

13. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011;15:1593-1602.
PUBMED | CROSSREF

14. Vaksman O, Trope C, Davidson B, Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014;35:2113-2120.
PUBMED | CROSSREF

15. Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro M, Hirakawa K, et al. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. PLoS One 2015;10:e0130472.
PUBMED | CROSSREF

16. Yamamoto CM, Oakes ML, Murakami T, Muto MG, Berkowitz RS, Ng SW. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. J Ovarian Res 2018;11:20.
PUBMED | CROSSREF

17. Záveský L, Jandáková E, Weinberger V, Minár L, Hanžíková V, Dušková D, et al. Ascites-derived extracellular microRNAs as potential biomarkers for ovarian cancer. Reprod Sci 2019;26:510-522.
PUBMED | CROSSREF

18. Schindler P, Kupcinskas J, Juzenas S, Skieceviciene J, Salteniene V, Schulz C, et al. Expression of microRNAs in the ascites of patients with peritoneal carcinomatosis and peritonitis. Cancer Cytopathol 2018;126:353-363.
PUBMED | CROSSREF

19. Kaleta EJ, Tolan NV, Ness KA, O’Kane D, Algeciras-Schimnich A, CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation. Clin Biochem 2013;46:814-818.
PUBMED | CROSSREF

20. Zhu FL, Ling AS, Wei Q, Ma J, Lu G. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites. Asian Pac J Cancer Prev 2015;16:719-722.
PUBMED | CROSSREF

https://jgc-online.org

https://doi.org/10.5230/jgc.2019.19.e27
21. Chubb SP, Williams RA. Biochemical analysis of pleural fluid and ascites. Clin Biochem Rev 2018;39:39-50.

22. Jung M, Jeung HC, Lee SS, Park JY, Hong S, Lee SH, et al. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol 2010;136:517-526.

23. Song SE, Choi P, Kim JH, Jung K, Kim SE, Moon W, et al. Diagnostic value of carcinoembryonic antigen in ascites for colorectal cancer with peritoneal carcinomatosis. Korean J Gastroenterol 2018;71:332-337.

24. Tian F, Shen Y, Chen Z, Li R, Lu J, Ge Q, Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene 2016;591:338-343.

25. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to 5-FU in colon cancer. Cancer Genomics Proteomics 2006;3:317-324.

26. Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 2014;9:e96228.

27. Shi ZM, Wang XF, Qian X, Tao T, Wang L, Chen QD, et al. miRNA-181b suppresses IGF-1R, and functions as a tumor suppressor gene in gliomas. RNA 2013;19:552-560.

28. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between miRNA expression and progression and prognosis of gastric cancer: a miRNA expression analysis. Lancet Oncol 2010;11:136-146.

29. Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifuridine/Oxaliplatin. PLoS One 2011;6:e23271.

30. Saito M, Okayama H, Saito K, Ando J, Kumamoto K, Nakamura I, et al. CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer. Oncol Lett 2017;14:6184-6190.

31. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 2011;9:824-833.

32. Huang S, Wang J, Li J, Luo Q, Zhao M, Zheng L, et al. Serum microRNA expression profile as a diagnostic panel for gastric cancer. Jpn J Clin Oncol 2016;46:811-818.

33. Chen L, Yang Q, Kong WQ, Liu T, Liu M, Li X, et al. MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. IUBMB Life 2012;64:628-635.

34. Li LQ, Yang Y, Chen H, Zhang L, Pan D, Xie WJ. MicroRNA-181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene. Cancer Biomark 2016;17:75-81.

35. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 2012;421:4-8.

36. Yuppaplanchi R, Liang T, Goswami CP, Nalamasu R, Li L, Jones D, et al. Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One 2013;8:e74471.

37. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011;120:183-193.